# TECELRA (afamitresgene autoleucel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/afamitresgene-autoleucel

> The FDA approved TECELRA (afamitresgene autoleucel), sponsored by Adaptimmune Therapeutics PLC (ADAPY), on December 31, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is TECELRA (afamitresgene autoleucel) FDA approved?

Yes. The FDA approved TECELRA (afamitresgene autoleucel), sponsored by Adaptimmune Therapeutics PLC (ADAPY), on December 31, 2024. SEC Form 10-K: "As of December 31, 2024, the Company's only commercially approved product was TECELRA® ("TECELRA"), which was approved by the FDA on August 1, 2024." [Calendar and source filings](https://sec-api.dev/pdufa/afamitresgene-autoleucel)

Source: SEC Form 10-K, accession 0001558370-25-003544, https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm (retrieved 2026-11-12). Last confirmed 2025-03-24. Cite: https://sec-api.dev/pdufa/afamitresgene-autoleucel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | TECELRA (afamitresgene autoleucel) |
| Codes |  |
| Sponsor | Adaptimmune Therapeutics PLC (ADAPY) https://sec-api.dev/companies/adapy/catalysts |
| Indications | advanced synovial sarcoma and, advanced mage-a4+ synovial sarcoma in adults with certain hla types, solid tumor cancer approved |
| Modality | cell_therapy |
| FDA designations | none disclosed |

## Timeline

### August 1, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: advanced synovial sarcoma and.
- First seen 2024-11-13, last confirmed 2025-10-20.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-100618): "In August 2024, the U.S. Food and Drug Administration ("FDA") approved our first biologics license application ("BLA") for TECELRA® (afamitresgene autoleucel) ("TECELRA"), which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S. In July 2025, TECELRA was acquired by US WorldMeds alongside letetresgene autoleucel ("lete-cel"), for people with synovial sarcoma and myxoid liposarcoma, in relation to which a commercial launch was planned for 2026." https://www.sec.gov/Archives/edgar/data/1621227/000110465925100618/adap-20251015xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011304): "The product revenue has increased due to product sales commencing following the FDA approval of TECELRA on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007493): "Revenue has increased primarily due to $4.0 million in product sales following the FDA approval of TECELRA on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837025007493/adap-20250513xex99d1.htm
- SEC Form 10-Q (accession 0001558370-25-011307): "On August 1, 2024, the Company received FDA approval for TECELRA for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy, and commenced capitalization of inventory from this date." https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/adap-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011307): "We have been focused on the commercialization of TECELRA for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/adap-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011307): "After, the Company received FDA approval on August 1, 2024, for TECELRA for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy, the Company started generating product revenue from sales of TECELRA." https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/adap-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007571): "On August 1, 2024, the Company received FDA approval for TECELRA for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy, and commenced capitalization of inventory from this date." https://www.sec.gov/Archives/edgar/data/1621227/000155837025007571/adap-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007571): "We are focused on the commercialization of TECELRA for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837025007571/adap-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003544): "We are focused on the commercialization of TECELRA for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003544): "On August 1, 2024, the Company received FDA approval for TECELRA for the treatment of advanced MAGE-A4+ synovial sarcoma in adults with certain HLA types who have received prior chemotherapy, and commenced capitalization of inventory from this date." https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015532): "We are focused on the launch and commercialization of Tecelra for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837024015532/adap-20240930x10q.htm

### December 31, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001558370-25-003544): "As of December 31, 2024, the Company's only commercially approved product was TECELRA® ("TECELRA"), which was approved by the FDA on August 1, 2024." https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/afamitresgene-autoleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TECELRA (afamitresgene autoleucel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/afamitresgene-autoleucel

```bibtex
@misc{secapidev_pdufa_afamitresgene_autoleucel_20261116,
  title        = {TECELRA (afamitresgene autoleucel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/afamitresgene-autoleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_afamitresgene_autoleucel_20261116","title":"TECELRA (afamitresgene autoleucel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/afamitresgene-autoleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
